Clinical trial Recruiting at 1 site Observational Ages 20 and up

Using metabolomics to predict treatment response in rectal cancer

Official title: Metabolomic Profiles as Predictors of Treatment Response and Toxicities in Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy

Run by Chang Gung Memorial Hospital · NCT06831669 · Data updated 2026-11-12

This study is testing whether certain substances in the body can help predict how well patients with advanced rectal cancer will respond to a specific treatment plan and if they might face any side effects.

Quick facts

Study typeObservational
Ages20 Years and up
SexAll
Enrollment250 (estimated)
SponsorChang Gung Memorial Hospital
Academic / other
Drugs / interventionsradiation, chemotherapy
Locations1 site (Guishan, Taoyuan)
StatusRecruiting
StartedJanuary 5, 2024
Main results expectedDecember 12, 2028
Study endsDecember 12, 2033
Registry record updatedApril 15, 2026
Trial IDNCT06831669 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals with histologically confirmed adenocarcinoma of the rectum who are scheduled to receive total neoadjuvant therapy.

Probably not a fit

Patients who have previously undergone pelvic radiation therapy or have inflammatory bowel disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the metabolomic profiles of patients with locally advanced rectal cancer who are scheduled to receive total neoadjuvant therapy (TNT). By collecting blood, urine, tissue, and fecal samples at various stages of treatment, the study seeks to identify specific metabolites that can predict how well patients will respond to TNT and the likelihood of experiencing treatment-related toxicities, such as radiation proctitis. The goal is to enhance precision health by selecting patients who are most likely to benefit from TNT while minimizing complications.

Why it matters

Potential benefit: If successful, this study could lead to personalized treatment plans that improve outcomes and reduce side effects for rectal cancer patients.

How similar studies have gone: There is a growing body of evidence suggesting that metabolomics can effectively predict treatment response and toxicity in cancer patients, although most prior studies have focused on long-course chemoradiotherapy.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the rectum
* Scheduled to receive total neoadjuvant therapy

Exclusion Criteria:

* Previous pelvic radiation therapy
* Inflammatory bowel disease

Where it's running

  • Linkou Chang Gung Memorial Hospital
    Guishan, Taoyuan, Taiwan
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.